{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:20:48Z","timestamp":1791566448514,"version":"4.3.4"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016059"],"award-info":[{"award-number":["P30 CA016059"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA239706"],"award-info":[{"award-number":["R01 CA239706"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03 CA235097"],"award-info":[{"award-number":["R03 CA235097"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oral. Health"],"abstract":"<jats:p>Head and neck cancer is the sixth leading cancer worldwide; head and neck squamous cell carcinoma (HNSCC) accounts for more than 90% of incident cases. In the US, cases of HNSCC associated with human papillomavirus (HPV) have been growing in proportion amongst a younger demographic with superior outcomes to the same treatments, relative to cases associated with tobacco. Yet failures to improve the long-term prognosis of advanced HNSCC over the last three decades persist in part due to intrinsic and acquired mechanisms of resistance. Deregulation of the pathways to respond to stress, such as apoptosis and autophagy, often contributes to drug resistance and tumor progression. Here we review the stress-response pathways in drug response and resistance in HNSCC to explore strategies to overcome these resistance mechanisms. We focus on the mechanisms of resistance to current standard cares, such as chemotherapy (i.e., cisplatin), radiation, and cetuximab. Then, we discuss the strategies to overcome these resistances, including novel combinations and immunotherapy.<\/jats:p>","DOI":"10.3389\/froh.2021.676643","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T06:46:22Z","timestamp":1624430782000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer"],"prefix":"10.3389","volume":"2","author":[{"given":"Tasia","family":"Bos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alex","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2982","article-title":"The molecular biology of head and neck cancer","volume":"11","author":"Leemans","year":"2011","journal-title":"Nat Rev Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41419-019-1769-9","article-title":"Clinical update on head and neck cancer: molecular biology and ongoing challenges","volume":"10","author":"Alsahafi","year":"2019","journal-title":"Cell Death Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1172\/JCI59889","article-title":"The molecular pathogenesis of head and neck squamous cell carcinoma","volume":"122","author":"Rothenberg","year":"2012","journal-title":"J Clin Investig."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3892\/or_00000974","article-title":"Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck","volume":"24","author":"Schultz","year":"2010","journal-title":"Oncol Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0305-7372(03)00139-7","article-title":"Platinum-based chemotherapy in metastatic breast cancer: current status","volume":"30","author":"Decatris","year":"2004","journal-title":"Cancer Treat Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat Rev Drug Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/nrc1451","article-title":"Radiation oncology: a century of achievements","volume":"4","author":"Bernier","year":"2004","journal-title":"Nat Rev Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and radiation therapy: current advances and future directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int J Med Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"9530","DOI":"10.1038\/s41598-020-66351-9","article-title":"Local tissue electrical parameters predict oral mucositis in HNSCC patients: a diagnostic accuracy double-blind, randomized controlled trial","volume":"10","author":"Sanches","year":"2020","journal-title":"Sci Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.3390\/ijms20184472","article-title":"Inflammaging and oxidative stress in human diseases: from molecular mechanisms to novel treatments","volume":"20","author":"Zuo","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature."},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrm1546","article-title":"p53: traffic cop at the crossroads of DNA repair and recombination","volume":"6","author":"Sengupta","year":"2005","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science."},{"key":"B18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/0022034518759068","article-title":"Targeting the DNA damage response in OSCC with TP53 mutations","volume":"97","author":"Lindemann","year":"2018","journal-title":"J Dent Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1158\/0008-5472.CAN-14-2735","article-title":"Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer","volume":"75","author":"Neskey","year":"2015","journal-title":"Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.celrep.2013.04.012","article-title":"p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa","volume":"3","author":"Valente","year":"2013","journal-title":"Cell Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc2693","article-title":"When mutants gain new powers: news from the mutant p53 field","volume":"9","author":"Brosh","year":"2009","journal-title":"Nat Rev Cancer."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat Cell Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/jcb.25592","article-title":"TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response","volume":"117","author":"Zhou","year":"2016","journal-title":"J Cell Biochem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/ncb1571","article-title":"p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM","volume":"9","author":"Song","year":"2007","journal-title":"Nat Cell Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(10)70017-6","article-title":"HPV-associated head and neck cancer: a virus-related cancer epidemic","volume":"11","author":"Marur","year":"2010","journal-title":"Lancet Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.gendis.2014.07.002","article-title":"Unraveling the molecular genetics of head and neck cancer through genome-wide approaches","volume":"1","author":"Riaz","year":"2014","journal-title":"Genes Dis."},{"key":"B27","first-page":"927","article-title":"Functional p53 protein in human papillomavirus-positive cancer cells","volume":"10","author":"Butz","year":"1995","journal-title":"Oncogene."},{"key":"B28","doi-asserted-by":"publisher","first-page":"931813","DOI":"10.5402\/2011\/931813","article-title":"The role of p53 and MDM2 in head and neck cancer","volume":"2011","author":"Denaro","year":"2011","journal-title":"ISRN Otolaryngol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.5301\/jbm.5000192","article-title":"Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up","volume":"31","author":"Vivenza","year":"2016","journal-title":"Int J Biol Mark."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1038\/sj.onc.1208419","article-title":"PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis","volume":"24","author":"Bykov","year":"2005","journal-title":"Oncogene."},{"key":"B31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fonc.2016.00021","article-title":"Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy","volume":"6","author":"Bykov","year":"2016","journal-title":"Front Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"37137","DOI":"10.18632\/oncotarget.26440","article-title":"The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants","volume":"9","author":"Omar","year":"2018","journal-title":"Oncotarget."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/cdd.2011.71","article-title":"SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis","volume":"18","author":"Li","year":"2011","journal-title":"Cell Death Differ."},{"key":"B34","doi-asserted-by":"publisher","first-page":"583","DOI":"10.4103\/0973-1482.126451","article-title":"Emphasizing on heat shock protein 90's utility in head and neck squamous cell carcinoma treatment","volume":"9","author":"Routray","year":"2013"},{"key":"B35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12885-017-3084-0","article-title":"HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation","volume":"17","author":"McLaughlin","year":"2017","journal-title":"BMC Cancer."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","article-title":"The Bcl-2 apoptotic switch in cancer development and therapy","volume":"26","author":"Adams","year":"2007","journal-title":"Oncogene."},{"key":"B37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol Cell."},{"key":"B39","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41419-019-2150-8","article-title":"Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck","volume":"10","author":"Carter","year":"2019","journal-title":"Cell Death Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1038\/sj.bjc.6602647","article-title":"Bcl-2 expression predicts radiotherapy failure in laryngeal cancer","volume":"92","author":"Nix","year":"2005","journal-title":"Br J Cancer."},{"key":"B41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/carcin\/bgy135","article-title":"STAT3- and GSK3beta-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma","volume":"40","author":"Maji","year":"2019","journal-title":"Carcinogenesis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/cdd.2017.183","article-title":"Why do BCL-2 inhibitors work and where should we use them in the clinic?","volume":"25","author":"Montero","year":"2018","journal-title":"Cell Death Differ."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.molcel.2020.05.014","article-title":"Cell death in the origin and treatment of cancer","volume":"78","author":"Strasser","year":"2020","journal-title":"Mol Cell."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1124\/mol.108.052969","article-title":"ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway","volume":"75","author":"Li","year":"2009","journal-title":"Mol Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"16731","DOI":"10.18632\/oncotarget.7744","article-title":"Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC","volume":"7","author":"Gilormini","year":"2016","journal-title":"Oncotarget."},{"key":"B46","doi-asserted-by":"publisher","first-page":"494","DOI":"10.18632\/oncotarget.26563","article-title":"Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1","volume":"10","author":"Ow","year":"2019","journal-title":"Oncotarget."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0219398","DOI":"10.1371\/journal.pone.0219398","article-title":"Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment","volume":"14","author":"Britt","year":"2019","journal-title":"PLoS ONE."},{"key":"B48","doi-asserted-by":"publisher","first-page":"8581","DOI":"10.1038\/sj.onc.1207113","article-title":"Survivin, versatile modulation of cell division and apoptosis in cancer","volume":"22","author":"Altieri","year":"2003","journal-title":"Oncogene."},{"key":"B49","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/70242","article-title":"Pleiotropic cell-division defects and apoptosis induced by interference with survivin function","volume":"1","author":"Li","year":"1999","journal-title":"Nat Cell Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.4161\/cc.3.9.1093","article-title":"An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy","volume":"3","author":"Zangemeister-Wittke","year":"2004","journal-title":"Cell Cycle."},{"key":"B51","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jcb.21836","article-title":"Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway","volume":"105","author":"Croci","year":"2008","journal-title":"J Cell Biochem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"969","DOI":"10.4161\/auto.6822","article-title":"CCL2, survivin and autophagy: new links with implications in human cancer","volume":"4","author":"Roca","year":"2008","journal-title":"Autophagy."},{"key":"B53","doi-asserted-by":"publisher","first-page":"bio037374","DOI":"10.1242\/bio.037374","article-title":"Survivin inhibits excessive autophagy in cancer cells but does so independently of its interaction with LC3","volume":"7","author":"Humphry","year":"2018","journal-title":"Biol Open."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3109\/00016480902856588","article-title":"Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges","volume":"130","author":"Marioni","year":"2010","journal-title":"Acta Otolaryngol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s11658-017-0038-0","article-title":"Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma","volume":"22","author":"Khan","year":"2017","journal-title":"Cell Mol Biol Lett."},{"key":"B56","doi-asserted-by":"publisher","first-page":"105049","DOI":"10.1016\/j.oraloncology.2020.105049","article-title":"Survivin expression and impact on head and neck cancer outcomes","volume":"112","author":"Khan","year":"2021","journal-title":"Oral Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ijc.22941","article-title":"Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential","volume":"121","author":"Lippert","year":"2007","journal-title":"Int J Cancer."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3390\/ijms19092664","article-title":"Integrative histologic and bioinformatics analysis of birc5\/survivin expression in oral squamous cell carcinoma","volume":"19","author":"Troiano","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1080\/15384101.2017.1310352","article-title":"Nuclear survivin promoted by acetylation is associated with the aggressive phenotype of oral squamous cell carcinoma","volume":"16","author":"Liu","year":"2017","journal-title":"Cell Cycle."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.3892\/or.2019.7082","article-title":"Survivin overexpression in head and neck squamous cell carcinomas as a new therapeutic target (Review)","volume":"41","author":"Frassanito","year":"2019","journal-title":"Oncol Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1158\/1535-7163.MCT-12-0167","article-title":"YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels","volume":"11","author":"Kumar","year":"2012","journal-title":"Mol Cancer Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e1771","DOI":"10.1038\/cddis.2015.139","article-title":"Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma","volume":"6","author":"Zhang","year":"2015","journal-title":"Cell Death Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/bph.12935","article-title":"YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells","volume":"172","author":"Cheng","year":"2015","journal-title":"Br J Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1158\/1078-0432.CCR-08-1946","article-title":"Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors","volume":"15","author":"Satoh","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1200\/JCO.2008.21.1862","article-title":"Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer","volume":"27","author":"Giaccone","year":"2009","journal-title":"J Clin Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/annonc\/mdt249","article-title":"A phase I\/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer","volume":"24","author":"Kelly","year":"2013","journal-title":"Ann Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/imr.12541","article-title":"Caspase-8: regulating life and death","volume":"277","author":"Tummers","year":"2017","journal-title":"Immunol Rev."},{"key":"B68","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/2159-8290.CD-12-0537","article-title":"Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers","volume":"3","author":"Pickering","year":"2013","journal-title":"Cancer Discov."},{"key":"B69","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-15-0365","article-title":"Promises and Challenges of Smac Mimetics as Cancer Therapeutics","volume":"21","author":"Fulda","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e139837","DOI":"10.1172\/jci.insight.139837","article-title":"Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis","volume":"5","author":"Uzunparmak","year":"2020","journal-title":"JCI Insight."},{"key":"B71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3290\/j.cjdr.a35694","article-title":"Molecular mechanisms of chemoresistance in oral cancer","volume":"19","author":"Wang","year":"2016","journal-title":"Chin J Dent Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1038\/s41388-020-1250-3","article-title":"Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizer","volume":"39","author":"Hutchinson","year":"2020","journal-title":"Oncogene."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-10-2641","article-title":"DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy","volume":"17","author":"Moeller","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e39588","DOI":"10.1371\/journal.pone.0039588","article-title":"Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response","volume":"7","author":"Li","year":"2012","journal-title":"PLoS ONE."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6602823","article-title":"Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026","volume":"93","author":"Nutley","year":"2005","journal-title":"Br J Cancer."},{"key":"B76","doi-asserted-by":"publisher","first-page":"25833","DOI":"10.18632\/oncotarget.25383","article-title":"VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells","volume":"9","author":"Khan","year":"2018","journal-title":"Oncotarget."},{"key":"B77","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1158\/0008-5472.CAN-07-6636","article-title":"Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair","volume":"68","author":"Chen","year":"2008","journal-title":"Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.cell.2012.11.054","article-title":"An inhibitor of non-homologous end-joining abrogates double-strand break repair and impedes cancer progression","volume":"151","author":"Srivastava","year":"2012","journal-title":"Cell."},{"key":"B79","doi-asserted-by":"publisher","first-page":"81662","DOI":"10.18632\/oncotarget.20953","article-title":"Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers","volume":"8","author":"Glorieux","year":"2017","journal-title":"Oncotarget."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1158\/1535-7163.MCT-13-0157","article-title":"Chk1\/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53","volume":"12","author":"Gadhikar","year":"2013","journal-title":"Mol Cancer Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1158\/0008-5472.CAN-17-2802","article-title":"CDKN2A\/p16 deletion in head and neck cancer cells is associated with CDK2 activation, replication stress, and vulnerability to CHK1 inhibition","volume":"78","author":"Gadhikar","year":"2018","journal-title":"Cancer Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-17-3796","article-title":"A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly docetaxel and cisplatin before definitive therapy in head and neck squamous cell carcinoma","volume":"24","author":"Mendez","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e033009","DOI":"10.1136\/bmjopen-2019-033009","article-title":"Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol","volume":"10","author":"Kong","year":"2020","journal-title":"BMJ Open."},{"key":"B84","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell."},{"key":"B85","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/ncb1145","article-title":"ATR and ATM regulate the timing of DNA replication origin firing","volume":"6","author":"Shechter","year":"2004","journal-title":"Nat Cell Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-10-2537","article-title":"WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe","volume":"17","author":"De Witt Hamer","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/odi.12254","article-title":"Role of autophagy in head and neck cancer and therapeutic resistance","volume":"21","author":"Sannigrahi","year":"2015","journal-title":"Oral Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ijc.10503","article-title":"Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance","volume":"100","author":"Condon","year":"2002","journal-title":"Int J Cancer."},{"key":"B89","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2005.07.002","article-title":"Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy","volume":"122","author":"Pattingre","year":"2005","journal-title":"Cell."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1038\/cddis.2011.56","article-title":"Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy","volume":"2","author":"Kuwahara","year":"2011","journal-title":"Cell Death Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12032-009-9397-3","article-title":"Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells","volume":"28","author":"Liu","year":"2011","journal-title":"Med Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1002\/ijc.25300","article-title":"Concomitant inhibition of AKT and autophagy is required for efficient cisplatin-induced apoptosis of metastatic skin carcinoma","volume":"127","author":"Claerhout","year":"2010","journal-title":"Int J Cancer."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.biopha.2017.11.024","article-title":"Cancer-associated fi broblasts confer cisplatin resistance of tongue cancer via autophagy activation","volume":"97","author":"Liao","year":"2018","journal-title":"Biomed Pharmacother."},{"key":"B94","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1158\/0008-5472.CAN-17-1077","article-title":"Secretory autophagy in cancer-associated fibroblasts promotes head and neck cancer progression and offers a novel therapeutic target","volume":"77","author":"New","year":"2017","journal-title":"Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.oraloncology.2011.02.009","article-title":"Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer","volume":"47","author":"Sayed","year":"2011","journal-title":"Oral Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/hed.21801","article-title":"Cancer stem cells in head and neck squamous cell carcinoma: a review of current knowledge and future applications","volume":"34","author":"Bhaijee","year":"2012","journal-title":"Head Neck."},{"key":"B97","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0022034512467352","article-title":"Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma","volume":"92","author":"Scanlon","year":"2013","journal-title":"J Dent Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3892\/or.2014.3664","article-title":"miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through Twist","volume":"33","author":"Peng","year":"2015","journal-title":"Oncol Rep."},{"key":"B99","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.stem.2017.02.003","article-title":"Targeting BMI1(+) cancer stem cells overcomes chemoresistance and inhibits metastases in squamous cell carcinoma","volume":"20","author":"Chen","year":"2017","journal-title":"Cell Stem Cell."},{"key":"B100","doi-asserted-by":"publisher","first-page":"9118","DOI":"10.1002\/jcp.27589","article-title":"CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist\/Bmi1\/Akt pathway in head and neck squamous cell carcinoma","volume":"234","author":"Lai","year":"2019","journal-title":"J Cell Physiol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer."},{"key":"B102","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1158\/1078-0432.CCR-18-0871","article-title":"Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics","volume":"25","author":"Miyauchi","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1158\/1535-7163.MCT-14-1015","article-title":"Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer","volume":"14","author":"Mondini","year":"2015","journal-title":"Mol Cancer Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/bjc.2013.640","article-title":"Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer","volume":"110","author":"Balermpas","year":"2014","journal-title":"Br J Cancer."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/hed.24406","article-title":"Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma","volume":"38","author":"Nguyen","year":"2016","journal-title":"Head Neck."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4049\/jimmunol.0900734","article-title":"Chemotherapeutic agents in non-cytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism","volume":"183","author":"Shurin","year":"2009","journal-title":"J Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1172\/JCI43656","article-title":"Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice","volume":"121","author":"Lesterhuis","year":"2011","journal-title":"J Clin Investig."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J Clin Investig."},{"key":"B111","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","article-title":"Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1158\/1078-0432.CCR-10-0733","article-title":"A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers","volume":"16","author":"Kodumudi","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12026-015-8734-1","article-title":"Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model","volume":"64","author":"Huang","year":"2016","journal-title":"Immunol Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B116","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B117","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.20944\/preprints202008.0490.v2","article-title":"Immune escape mechanisms and their clinical relevance in head and neck squamous cell carcinoma","volume":"21","author":"Seliger","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.3390\/cancers12092691","article-title":"Immunotherapy breakthroughs in the treatment of recurrent or metastatic head and neck squamous cell carcinoma","volume":"12","author":"Borel","year":"2020","journal-title":"Cancers."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00018-017-2720-9","article-title":"Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma","volume":"75","author":"Chen","year":"2018","journal-title":"Cell Mol Life Sci."},{"key":"B120","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-017-0553-x","article-title":"The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma","volume":"36","author":"Feng","year":"2017","journal-title":"J Exp Clin Cancer Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1158\/1078-0432.CCR-12-2426","article-title":"Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients","volume":"19","author":"Srivastava","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B122","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fphar.2017.00382","article-title":"Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T cells in head and neck cancer patients","volume":"8","author":"Mazorra","year":"2017","journal-title":"Front Pharmacol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3390\/ijms20081822","article-title":"An update on anti-CD137 antibodies in immunotherapies for cancer","volume":"20","author":"Chu","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B124","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/1078-0432.CCR-16-0879","article-title":"CD137 Stimulation enhances cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer","volume":"23","author":"Srivastava","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B125","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1002\/hed.21109","article-title":"Mechanisms of resistance in head and neck cancer","volume":"10","author":"Picon","year":"2020","journal-title":"Am J Cancer Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2020.12.007","article-title":"Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma","volume":"39","author":"Huang","year":"2021","journal-title":"Cancer Cell."},{"key":"B128","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41389-019-0164-9","article-title":"Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI","volume":"8","author":"Yonesaka","year":"2019","journal-title":"Oncogenesis."},{"key":"B129","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1158\/0008-5472.CAN-14-0294","article-title":"AXL mediates resistance to cetuximab therapy","volume":"74","author":"Brand","year":"2014","journal-title":"Cancer Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1158\/1078-0432.CCR-12-0792","article-title":"Targeting Stat3 abrogates EGFR inhibitor resistance in cancer","volume":"18","author":"Sen","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bbrc.2019.06.159","article-title":"Differential escape mechanisms in cetuximab-resistant head and neck cancer cells","volume":"517","author":"Willey","year":"2019","journal-title":"Biochem Biophys Res Commun."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"J Clin Oncol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1177\/1947601913478972","article-title":"CDK4: a key player in the cell cycle, development, and cancer","volume":"3","author":"Baker","year":"2012","journal-title":"Genes Cancer."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00405-020-05891-2","article-title":"CDK4\/6 inhibitors in P16\/HPV16-negative squamous cell carcinoma of the head and neck","volume":"277","author":"Billard-Sandu","year":"2020","journal-title":"Eur Arch Otorhinolaryngol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(19)30405-X","article-title":"Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial","volume":"20","author":"Adkins","year":"2019","journal-title":"Lancet Oncol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fonc.2019.00155","article-title":"Phase 1 study evaluating the association of the cyclin-dependent kinase 4\/6 inhibitor ribociclib and cetuximab in recurrent\/metastatic p16-negative squamous cell carcinoma of the head and neck","volume":"9","author":"Seront","year":"2019","journal-title":"Front Oncol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41419-021-03474-5","article-title":"Cell death in head and neck cancer pathogenesis and treatment","volume":"12","author":"Raudenska","year":"2021","journal-title":"Cell Death Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"614332","DOI":"10.3389\/fonc.2021.614332","article-title":"Precision medicine approaches to overcome resistance to therapy in head and neck cancers","volume":"11","author":"Ortiz-Cuaran","year":"2021","journal-title":"Front Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"603160","DOI":"10.3389\/froh.2020.603160","article-title":"Major molecular signaling pathways in oral cancer associated with therapeutic resistance","volume":"1","author":"Usman","year":"2021","journal-title":"Front Oral Health."}],"container-title":["Frontiers in Oral Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2021.676643\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T18:45:20Z","timestamp":1624473920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2021.676643\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":139,"alternative-id":["10.3389\/froh.2021.676643"],"URL":"https:\/\/doi.org\/10.3389\/froh.2021.676643","relation":{},"ISSN":["2673-4842"],"issn-type":[{"value":"2673-4842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"article-number":"676643"}}